The development of PDGF receptor inhibitors for the treatment of Glioma: A review

Michael A. Badruddoja, Emad Elquza, James Welsh, Laurence Cooke, Abhay Sanan, Baldassrre Stea, Daruka Mahadavan

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


The platelet-derived growth factor (PDGF-A, PDGF-B, PDGF-C, PDGF-D) family is composed of homo- and hetero-dimers that are potent mitogens for a wide variety of cell types. They exert their biological effects by binding to two receptor tyrosine kinases (α- and β-PDGFR). PDGF-AA, -AB, -BB and -CC dimers bind to the α-PDGFR with high affinity, whereas PDGF-BB and -DD dimers bind to β-PDGFR. Aberrant PDGF signaling leads to increased interstitial fluid pressure, stromal cell recruitment and neo-angiogenesis in glioblastoma multiforme (GBM) due to deregulated autocrine/paracrine signaling. Therefore, targeting the PDGFR tyrosine kinase domain with small molecule tyrosine kinase inhibitors (TKIs) alone or in combination with chemotherapy may provide therapeutic benefit in GBM. Here we review PDGFR antagonists in clinical development including novel multi-targeted TKIs.

Original languageEnglish (US)
Pages (from-to)290-299
Number of pages10
JournalLetters in Drug Design and Discovery
Issue number4
StatePublished - May 2010


  • Clinical trials
  • Glioblastoma multiforme
  • Platelet derived growth factor receptor
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery


Dive into the research topics of 'The development of PDGF receptor inhibitors for the treatment of Glioma: A review'. Together they form a unique fingerprint.

Cite this